CBL-514 trial status: how to read the latest milestone

Caliway reported the first participant dosed in SUPREME-01 on 23 September 2026. The announcement identifies the study as CBL-0301, a pivotal Phase 3 trial, and the corresponding registry record is NCT07140939. These identifiers provide a concrete route to the study information and are more useful than a general claim that a product is “nearly approved.”

Treat the date as part of the fact. A sponsor announcement records what the company reported at that time; a registry entry may subsequently be updated. Compare the trial identifier, population, design and record history before interpreting recruitment or completion status. A first-participant milestone is not a completed efficacy analysis and does not establish a marketing authorization. This page was reviewed on 19 October 2026. Follow the linked primary records for subsequent changes rather than treating a static supplier summary as a live registry.

A clinical trial uses a defined investigational product under an authorized study framework. Its progress does not automatically authorize an unrelated business to manufacture, market or distribute a material under the same name. A supplier must establish its own lawful scope and provide the documents appropriate to the proposed transaction. The study sponsor’s manufacturing and testing arrangements cannot be borrowed as another company’s credentials.

For procurement teams, record development status and supply status in separate fields. The first describes the research program; the second describes the actual material, seller, destination and intended use under review. Do not infer an approved indication, retail availability or a launch date from a Phase 3 headline. If you are seeking participation in research, use the official study contact route. If you need a laboratory project review, describe that scope directly without assuming access to clinical trial supplies.